Technology & Pipeline

Novaremed holds a highly innovative and attractive compound pipeline that is based on its proprietary library of small molecules identified from a biological substance with anti-inflammatory therapeutic properties. Novaremed's lead compound - NRD135S-E1 – is in development for neuropathic pain.

Neuropathic pain is a chronic, debilitating condition with an estimated prevalence of one per cent of the general population. The majority of patients (more than 70%) are reported to suffer from moderate-to-severe forms of pain. According to recent studies, two thirds of the patients suffer for more than one year, with around half of the patients suffering for more than three years.

The causes of neuropathic pain are diverse and include diabetes (diabetic neuropathy), cancer or its treatment with therapy agents (e.g., chemotherapy-induced neuropathy), viruses (e.g., postherpetic neuralgia) and nerve trauma (peripheral nerve injury-induced neuropathy).

The market for neuropathic pain treatments is growing and expected to surpass US$ 5 billion by 2018.

Neuropathic pain is one of the most difficult types of chronic pain to treat, and relief is often unsatisfactory or short-term. Since treatment options are limited, doctors often prescribe a combination of therapies in an attempt to relieve symptoms. Existing therapies come from the drug classes of antidepressants, anticonvulsant agents and opioids.

NRD135S-E1 is a first-in-class tyrosine kinase modulator for the treatment of neuropathic pain via a unique and new mechanism of action. In pain-related animal models, NRD135S-E1 has demonstrated a significantly higher efficacy and better safety profile than the existing medications in use for this indication.

Novaremed has concluded a successful Phase I clinical study in healthy volunteers upon which the tested drug has been proven to be safe and well tolerated. Currently - the Company is conducting a Phase IIa clinical study in diabetic patients suffering from neuropathic pain in 10 medical sites in Israel.

Novaremed has additional pre-clinical programs under development.